Jacob Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacob Fang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Aishwarya Sahasrabudhe
Department of Biology, Center for Biological Clocks Research, Texas A&M University, College Station, TX 77843, USA
21 shared publications - Amenech B. Ashango
Hematologics, Inc., Seattle, Washington
21 shared publications - Andy Kaempf
Cancer Data Science Shared Resource OHSU, Knight Cancer Institute Portland Oregon USA
21 shared publications - Anupriya Agarwal
Division of Oncological Sciences, Oregon Health & Science University, United States
21 shared publications - Arpita Gandhi
Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA
21 shared publications - Ashley M. Eckel
Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA
21 shared publications
Latest Publications
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with isolated mutations/mutation groups were wild-type for all other genes tested (NPM1, IDH1/2, N/KRAS, FLT3-ITD, and TP53) except for the gene of interest. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on monocytic differentiation status censored at HCT for patients within specific mutation subgroups including (A) combined RAS pathway mutations (N/KRAS and PTPN11), and isolated mutations in (B) FLT3-ITD, (C) NRAS, (D) KRAS, (E) PTPN11, and (F) TP53. Patients with isolated mutations/mutation groups were wild-type for all other genes tested (NPM1, IDH1/2, N/KRAS, FLT3-ITD, and TP53) except for the gene of interest. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in patients classified as monocytic vs. non-monocytic in (A) patients classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53), (B) with mutated IDH1/2 and wild-type for N/KRAS, PTPN11, FLT3-ITD, and TP53, and (C) wild-type for NPM1, FLT3-ITD, IDH1/2, K/NRAS, PTPN11, and TP53. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in patients classified as monocytic vs. non-monocytic in (A) patients classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53), (B) with mutated IDH1/2 and wild-type for N/KRAS, PTPN11, FLT3-ITD, and TP53, and (C) wild-type for NPM1, FLT3-ITD, IDH1/2, K/NRAS, PTPN11, and TP53. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, and, in a small subset of cases with markedly hypogranular myeloids, by CD34 gate (these cases all contained an entirely CD34 positive blast population). Final gating for every case was reviewed by a pathologist. (B) For cells identified in the leukemia gate, the mean intensity for each parameter (represented by a black dot) was computed.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overview of immunophenotypic expression profiling. (A) Flow cytometry was performed on diagnostic bone marrow specimens and fluorescence measurements, forward light scatter (FSC) and right-angle light scatter (SSC) characteristics were collected for 200,000 events. Leukemic populations were identified by CD45 v SSC gating, and, in a small subset of cases with markedly hypogranular myeloids, by CD34 gate (these cases all contained an entirely CD34 positive blast population). Final gating for every case was reviewed by a pathologist. (B) For cells identified in the leukemia gate, the mean intensity for each parameter (represented by a black dot) was computed.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental FIgure 5 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival within the US cohort (n = 279) based on the presence of signaling pathway mutations including (A) NRAS, (B) KRAS, (C) PTPN11, (D) BRAF, (E) NF1, and (F) WT1. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Patient and disease characteristics for Beat AML RNAseq cohort (N = 228)
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Patient and disease characteristics for Beat AML RNAseq cohort (N = 228)
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival based on (A) NPM1 mutation status, (B) FLT3-ITD mutation status within NPM1 mutated cases only, (C) IDH1 mutation status, and (D) IDH2 mutation status. Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. ref: reference.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Surface expression of CD14, CD64, and CD11b in cases by genetic mutation compared to a wild-type reference cohort within the subset of patients with centralized quantitative MFC performed (n = 144). * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, **** indicates p < 0.0001. ref: reference.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
RNA expression of alternative anti-apoptotic proteins based on RNA-seq defined cell differentiation state. Samples from the top quartile of each state are displayed below.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
Overall survival in the subgroup of patients not receiving allogeneic cell transplantation (HCT) based on (A) monocytic vs. non-monocytic differentiation, (B) monocytic differentiation and NPM1 mutation status, (C) in the subgroup of patients with RAS pathway and FLT3-ITD mutations (K/NRAS, PTPN11, FLT3-ITD) and wild-type IDH1/2, NPM1, and TP53; (D) within the patient subgroup classified as mPRS higher-benefit (wild-type for FLT3, N/KRAS and TP53). Reported p-values utilized the cox model Wald test.
- Open Access
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
(A) mutation frequency within the Beat AML cohort (n = 228). (B) Heatmap depicting the point-biserial correlation values for RNAseq defined cell state scores in relationship to specific genetic mutations. (C) Heatmap depicting the point-biserial correlation values for RNA expression of primitive (CD34 and CD117) and monocytic markers of differentiation (CD11b, CD11c, CD14, CD64, CD4, CD36, and CD38) in relation to the top quartile of cases falling within each RNAseq defined cell-state.
- 7 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from Genetic and Phenotypic Correlates of Clinical Outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN Study
(A) mutation frequency within the Beat AML cohort (n = 228). (B) Heatmap depicting the point-biserial correlation values for RNAseq defined cell state scores in relationship to specific genetic mutations. (C) Heatmap depicting the point-biserial correlation values for RNA expression of primitive (CD34 and CD117) and monocytic markers of differentiation (CD11b, CD11c, CD14, CD64, CD4, CD36, and CD38) in relation to the top quartile of cases falling within each RNAseq defined cell-state.